ONCOVISTA INNOVATI COM STK USD0.01 (OVIT)

0.04
OTC Markets
Prev Close 0.05
Day Low/High 0.04 / 0.04
52 Wk Low/High 0.02 / 0.90
Exchange OTC Markets
Shares Outstanding 23.56B
Market Cap 1.18M
Div & Yield N.A. (N.A)

Oncovista Dormant

Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company") is dormant.

Oncovista Receives Bridge Financing

Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista or the "Company") is pleased to announce it has received bridge financing from two funding sources recently.

Oncovista Updates Investors On Financings And Strategic Options

Oncovista Innovative Therapies, Inc. (OTCBB:OVIT) ("OncoVista" or the "Company") is pleased to announce that it currently is being courted by three funding sources for a significant equity financing, one of which has...

Oncovista Retains Great Plains Capital As A Financial Advisor

Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company") is pleased to announce it has retained Great Plains Capital Partners, LLC ("GPCP" or "advisor") as a financial advisor.

Oncovista Settles 3 Year Litigation In New York Supreme Court

Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company") is pleased to announce its 3 year litigation has been settled favorably in the New York Supreme Court.

OncoVista Innovative Therapies Initiates Additional Safety Study Of OVI-117

OncoVista Innovative Therapies, Inc. (OTCBB:OVIT) reported that it has initiated an additional safety study of OVI-117 in a 2 nd animal species.

OncoVista Innovative Therapies Outlines Business Strategy; “Company Is Moving Full-Speed Ahead,” Says CEO

OncoVista Innovative Therapies, Inc., (OTCBB:OVIT) reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or...

OncoVista Sells AdnaGen Subsidiary: Total Sale Price Could Reach $65 Million Over Three Years When Milestones Achieved

OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biopharmaceutical company commercializing diagnostic tests for metastatic tumors, as well as developing targeted, personal anticancer therapies...

OncoVista Subsidiary Grants Option To License Proprietary Antibodies To KellBenx Inc.

AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc.

OncoVista Inc. Updates With Comprehensive Shareholder Letter

OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments,...

OncoVista Inc. Reports Sharply Higher Q1 Revenues

OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments,...